Individualized Prediction of Postoperative Survival in Gallbladder Cancer: A Nomogram Based on SEER Data and External Validation
Open Access
Abstract
Background: Gallbladder cancer (GBC) is a rare but aggressive malignancy. Prognostic tools are essential for optimizing postoperative treatment strategies. We aim to develop and validate a prognostic nomogram to estimate 1-, 3-, and 5-year overall survival (OS) in GBC patients and explore the role of adjuvant chemotherapy across different subgroups. Methods: A total of 1848 postoperative GBC patients from the SEER database (2000–2020 17 regions) were analyzed, with an additional external validation cohort of 108 patients from China (2010–2020). Prognostic factors were identified using LASSO regression and multivariable Cox analysis. A nomogram was constructed and validated using the concordance index (C-index), time-dependent ROC curves, calibration curves, and decision curve analysis (DCA). Subgroup analyses were performed to evaluate the impact of adjuvant chemotherapy. Results: The nomogram demonstrated strong predictive performance, with C-indices of 0.767 (training), 0.798 (internal validation), and 0.750 (external validation). Time-dependent ROC curves in the training cohort showed AUCs of 0.777, 0.769, and 0.800 for 1-, 3-, and 5-year OS, respectively. In the internal validation cohort, the corresponding AUCs were 0.763, 0.743, and 0.803. External validation using the independent Chinese cohort of 108 patients showed consistent results, with AUCs of 0.771, 0.835, and 0.810 for 1-, 3-, and 5-year OS. Subgroup analysis revealed that adjuvant chemotherapy significantly improved survival in patients with TNM stage >IIB. In contrast, patients with early-stage disease (TNM ≤ IIB) showed no significant survival benefit from chemotherapy. Conclusions: This study developed a validated prognostic nomogram for postoperative GBC patients, demonstrating strong discrimination and calibration. Subgroup analysis suggests that adjuvant chemotherapy benefits select high-risk patients, aiding personalized decision-making in clinical practice.Keywords
Funding Information
- National Natural Science Foundation of China (82173317, 82373365, GDXZ-08-12)
- Beijing iGandan Foundation (82173317, 82373365, GDXZ-08-12)
This publication has 29 references indexed in Scilit:
- Adjuvant Gemcitabine Plus Cisplatin and Chemoradiation in Patients With Gallbladder CancerJAMA Oncology, 2024
- Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trialThe Lancet, 2023
- Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder CancerJAMA Network Open, 2022
- Current management of incidental gallbladder cancer: A reviewInternational Journal of Surgery, 2022
- Evaluation and analysis of incidence and risk factors of lower extremity venous thrombosis after urologic surgeries: A prospective two-center cohort study using LASSO-logistic regressionInternational Journal of Surgery, 2021
- Survival prediction for gallbladder carcinoma after curative resection: Comparison of nomogram and Bayesian network modelsEuropean Journal of Surgical Oncology, 2020
- A nomogram for predicting overall survival in patients with low‐grade endometrial stromal sarcoma: A population‐based analysisCancer Communications, 2020
- Current standards and future perspectives in adjuvant treatment for biliary tract cancersCancer Treatment Reviews, 2020
- Elevation of CA19-9 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinomaHPB, 2017